On September 15, Abivax S.A. fell 5.33% in regular trading, trading at $107.11/share, with turnover of approximately $32.65 million. The selloff appears driven by investor caution ahead of the company's upcoming earnings release.

Abivax S.A. is scheduled to report quarterly results on September 21 after market close. Consensus estimates project revenue of approximately EUR 678,900, representing a year-over-year decline of 43.05%. Adjusted earnings per share are expected at a loss of EUR 1.06, widening 33.33% compared to the prior-year period. EBIT is forecast at approximately negative EUR 55.59 million, though this represents a 15.29% narrowing year-over-year. Last quarter, the company posted revenue of EUR 994,000 with a 100% gross margin, while net loss attributable to shareholders reached EUR 48.47 million. The steep projected revenue decline and widening per-share losses likely prompted some investors to reduce positions ahead of the report.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases. Its lead candidate, obefazimod, is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)